Mon, May 10, 2010
Sun, May 9, 2010
Sat, May 8, 2010
Fri, May 7, 2010
Thu, May 6, 2010
Mon, January 11, 2010
Sat, January 9, 2010
Fri, January 8, 2010
Thu, January 7, 2010
Wed, January 6, 2010
Tue, January 5, 2010
Mon, January 4, 2010
[ Mon, Jan 04th 2010 ] - Market Wire
Cordani Becomes CIGNA CEO
Thu, December 31, 2009
[ Thu, Dec 31st 2009 ] - Market Wire
Quit the Board
Wed, December 30, 2009
Tue, December 29, 2009
Mon, December 28, 2009
Thu, December 24, 2009
Wed, December 23, 2009
Tue, December 22, 2009
Mon, December 21, 2009
Fri, December 18, 2009
[ Fri, Dec 18th 2009 ] - Market Wire
Akorn Announces Business Update

ARIAD to Present at the 28th Annual J.P. Morgan Healthcare Conference


//health-fitness.news-articles.net/content/2010/ .. 8th-annual-j-p-morgan-healthcare-conference.html
Published in Health and Fitness on Tuesday, January 5th 2010 at 3:40 GMT by Market Wire   Print publication without navigation


CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--[ ARIAD Pharmaceuticals, Inc. ] (NASDAQ: ARIA) today announced that it will present at the 28th Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, California. Harvey J. Berger, M.D., chairman and chief executive officer at ARIAD, will provide an overview of the Company and its progress in key programs on Wednesday, January 13, 2010 at 7:30 a.m. (PT).

The ARIAD presentation will be webcast live and can be accessed by visiting the investor relations section of the Company's website at [ http://www.ariad.com/investor ]. A replay will be available on the ARIAD website approximately twenty-four hours after the presentation and will be archived for three weeks.

About ARIAD

ARIAD's vision is to transform the lives of cancer patients with breakthrough medicines. The Company's mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need – aggressive cancers where current therapies are inadequate. ARIAD's lead product candidate, ridaforolimus, is an investigational mTOR inhibitor in Phase 3 clinical development in patients with advanced sarcomas and is being developed in collaboration with Merck & Co., Inc. ARIAD's second internally-discovered product candidate, AP24534, is an investigational pan-BCR-ABL inhibitor completing Phase 1 clinical development in patients with hematological cancers, notably chronic myeloid leukemia. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-κB cell-signaling activity, which may be useful in treating certain diseases. For additional information about the Company, please visit [ http://www.ariad.com ].


Publication Contributing Sources